CorMedix Inc.
CRMDNASDAQHealthcare● Active
$8.54
+$0.18(+2.15%)
Market Cap$669979149
P/E Ratio—
52W High$17.43
52W Low$6.13
CorMedix Inc. (CRMD) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CRMD · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 14, 2026EPS Actual
$0.43
Est. $0.35 · +22.9%
Revenue
$0.13B
Est. $0.10B · +21.4%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 14, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue✓ 1-Quarter EPS Beat Streak
CRMD reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | $0.26 | — | — | — | $0.09B | — |
| ▲ Q2 FY2026 | May 14, 2026 | $0.35 | $0.43 | +22.9% | $0.13B | $0.10B | +21.4% |
| ▼ Q1 FY2026 | Mar 5, 2026 | $0.86 | $0.61 | -29.1% | $0.13B | $0.13B | +1.3% |
| ▲ Q4 FY2025 | Nov 12, 2025 | $0.48 | $0.57 | +18.8% | $0.10B | $0.13B | -17.9% |
| ▲ Q3 FY2025 | Aug 7, 2025 | $0.20 | $0.28 | +40.0% | $0.04B | $0.04B | -6.4% |
| ▲ Q2 FY2025 | May 6, 2025 | $0.25 | $0.30 | +20.0% | $0.04B | $0.03B | +30.8% |
| ▲ Q1 FY2025 | Mar 25, 2025 | $0.17 | $0.22 | +29.4% | $0.03B | $0.03B | -0.2% |
| ▲ Q4 FY2024 | Oct 30, 2024 | -$0.10 | -$0.05 | +50.0% | $0.01B | $0.02B | -42.1% |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
$0.26
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 14, 2026Beat
EPS Actual
$0.43
EPS Est.
$0.35
EPS Surpr.
+22.9%
Revenue
$0.13B
Q1 FY2026
Mar 5, 2026Miss
EPS Actual
$0.61
EPS Est.
$0.86
EPS Surpr.
-29.1%
Revenue
$0.13B
Q4 FY2025
Nov 12, 2025Beat
EPS Actual
$0.57
EPS Est.
$0.48
EPS Surpr.
+18.8%
Revenue
$0.10B
Q3 FY2025
Aug 7, 2025Beat
EPS Actual
$0.28
EPS Est.
$0.20
EPS Surpr.
+40.0%
Revenue
$0.04B
Q2 FY2025
May 6, 2025Beat
EPS Actual
$0.30
EPS Est.
$0.25
EPS Surpr.
+20.0%
Revenue
$0.04B
Q1 FY2025
Mar 25, 2025Beat
EPS Actual
$0.22
EPS Est.
$0.17
EPS Surpr.
+29.4%
Revenue
$0.03B
Q4 FY2024
Oct 30, 2024Beat
EPS Actual
-$0.05
EPS Est.
-$0.10
EPS Surpr.
+50.0%
Revenue
$0.01B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.42 | $0.43 | $0.44 | 1 |
| Q3 FY2028 | $0.40 | $0.42 | $0.43 | 1 |
| Q2 FY2028 | $0.41 | $0.42 | $0.43 | 1 |
| Q1 FY2028 | $0.40 | $0.41 | $0.42 | 1 |
| Q4 FY2027 | $0.10 | $0.10 | $0.10 | 1 |
| Q3 FY2027 | $0.07 | $0.07 | $0.07 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.1B | $0.1B | $0.1B | 1 |
| Q3 FY2028 | $0.1B | $0.1B | $0.1B | 1 |
| Q2 FY2028 | $0.1B | $0.1B | $0.1B | 1 |
| Q1 FY2028 | $0.1B | $0.1B | $0.1B | 1 |
| Q4 FY2027 | $0.1B | $0.1B | $0.1B | 1 |
| Q3 FY2027 | $0.1B | $0.1B | $0.1B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 14, 2026 | +22.9% | $7.50 | $7.93 | +5.73% |
| ▼ Q1 FY2026 | Mar 5, 2026 | -29.1% | $7.12 | $6.30 | -11.52% |
| ▲ Q4 FY2025 | Nov 12, 2025 | +18.8% | $11.19 | $11.42 | +2.06% |
| ▲ Q3 FY2025 | Aug 7, 2025 | +40.0% | $11.95 | $10.81 | -9.54% |
| ▲ Q2 FY2025 | May 6, 2025 | +20.0% | $9.03 | $11.16 | +23.59% |
| ▲ Q1 FY2025 | Mar 25, 2025 | +29.4% | $10.77 | $7.34 | -31.85% |
| ▲ Q4 FY2024 | Oct 30, 2024 | +50.0% | $12.97 | $10.05 | -22.51% |
| ▲ Q3 FY2024 | Aug 14, 2024 | +3.9% | $3.78 | $4.92 | +30.16% |
Q2 FY2026+5.73%
Report Date
May 14, 2026
EPS Beat/Miss
+22.9%
Price Before
$7.50
Price After
$7.93
Q1 FY2026-11.52%
Report Date
Mar 5, 2026
EPS Beat/Miss
-29.1%
Price Before
$7.12
Price After
$6.30
Q4 FY2025+2.06%
Report Date
Nov 12, 2025
EPS Beat/Miss
+18.8%
Price Before
$11.19
Price After
$11.42
Q3 FY2025-9.54%
Report Date
Aug 7, 2025
EPS Beat/Miss
+40.0%
Price Before
$11.95
Price After
$10.81
Q2 FY2025+23.59%
Report Date
May 6, 2025
EPS Beat/Miss
+20.0%
Price Before
$9.03
Price After
$11.16
Q1 FY2025-31.85%
Report Date
Mar 25, 2025
EPS Beat/Miss
+29.4%
Price Before
$10.77
Price After
$7.34
Q4 FY2024-22.51%
Report Date
Oct 30, 2024
EPS Beat/Miss
+50.0%
Price Before
$12.97
Price After
$10.05
Q3 FY2024+30.16%
Report Date
Aug 14, 2024
EPS Beat/Miss
+3.9%
Price Before
$3.78
Price After
$4.92
Avg Beat Reaction-0.34%
Avg Miss Reaction-11.52%
Beat Rate7 / 8 quarters
Largest Move-31.85% (Q1 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CRMD ends December
CorMedix Inc. (CRMD) most recently reported earnings on May 14, 2026 for Q2 FY2026, posting EPS of $0.43 — beating the analyst consensus of $0.35 by +22.9%. The next CRMD earnings date is expected around September 1, 2026.
Each quarter, investors track CRMD earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CRMD revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CRMD's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CRMD earnings · 5 questionsCorMedix Inc.'s next earnings report is expected around September 1, 2026. CRMD typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CRMD historically reports after market close (AMC).
CRMD earnings datewhen is CRMD earningsCRMD next earnings datewhen does CRMD report earningsCRMD earnings calendar
▸ Source: FMP · CorMedix Inc. SEC filings · US GAAP · CorMedix Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026